chemotherapy and radiation are the most important treatments for Her-2 negative breast cancer due to poor targeted therapy.Neoadjuvant chemotherapy has many advantages, for example, it can reduce tumor stage,to achieve surgical operation,maintain breast and armpit, and provide sensitive...
[8]Ogden A, Bhattarai S, Sahoo B, et al. Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Sci Rep. 2020;10(1):3009. [9]Sc...
PURPOSE: Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression is associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is being evaluated as a novel treatment in HE...
BREAST cancer treatmentHORMONE therapyCHI-squared testPROBABILITY theory1 of radiotherapy. Standard adjuvant systemic treatment for women with hormone-sensitive and HER-2 negative breast cancers is based on hormone therapy. Some women obtain additional benefit from chemotherapy, while others can avoid this...
(HER2-negative) breast cancer (n = 113; objective response rate [ORR], 30.1%; median progression-free survival [mPFS], 7.4 months), triple-negative breast cancer (n = 53; ORR, 22.6%; mPFS, 5.5 months), and HER2-positive breast cancer (n = 14;...
For the larger hormone-receptor positive and Her-2 negative subgroup, which concerns 75% of the patients, endocrine therapy and chemotherapy may be considered. Looking toward new-targeted therapies, this paper reviews the current use of these two treatment modalities in adjuvant, neoadjuvant and ...
Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials Park et al., "Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials," ... JB Lee,OH Woo,...
However, molecular targets and predictors for the treatment of triple negative breast carcinoma do not currently exist. METHODS AND RESULTS: This minireview focuses on biomarkers (HER1/EGFR, TOP2A and C-MYC genes) that may predict the response of triple negative breast carcinoma patients to ...
01-关于her-2阴性胃癌治疗 根据现行国际各大指南标准[5]，铂类联合氟尿嘧啶类药物为基础的全身化疗是晚期 HER-2 阴性胃癌的一线标准治疗，且化疗通常持续至直至疾病进展。然而铂类药物的累积毒性通常会使患者的身体状态进一步恶化。临床中，患者持续化疗至出现无法耐受的毒性后，通常使用氟尿嘧啶类药物单药治疗。此外，...
Long-term follow-up of these trials is needed to understand the role of bevacizumab treatment in BC and its important to find predictive biomarkers of response to this drug. 展开 关键词: breast cancer HER-2 neoadjuvant systemic therapy triple negative ...